All stock lists
Novo Nordisk A/S (New York Stock Exchange:NVO)
DK · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - General
40.19-0.26 (-0.64%)
Market cap
$179B
Insider Score
Health Score
Analyst consensus
Listed since
Apr 30, 1981
Website
Insider Score
––Not scored
NVO Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Strong
From NVO’s reported statements · Q2 2026 (trailing 12 months)
Profitability20 / 20
Keeps a healthy share of every dollar it sells.
- Revenue
- $329.43B
- Net income
- $116.44B
- Net margin
- 35.3%
Leverage17 / 20
Little or no net debt.
- Total debt
- $140.13B
- Cash
- $44.48B
- Net debt / EBITDA
- 0.53x
Liquidity5 / 20
Owes more within a year than it holds to pay it.
- Current assets
- $208.70B
- Current liabilities
- $239.08B
- Current ratio
- 0.87
Cash generation20 / 20
The business funds itself from operations.
- Operating cash flow
- $133.01B
- Free cash flow
- $48.92B
- FCF margin
- 14.8%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 4428.1M
- Share growth (1y)
- -0.4%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
NVO Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 78.49 B | 96.82 B | 79.14 B | 74.98 B | 76.86 B | 78.09 B |
| Revenue Growth (YoY) | 2.12 % | 23.99 % | -7.63 % | 5.14 % | 12.93 % | 19.49 % |
| Cost of Revenue | 17.10 B | 13.60 B | 15.15 B | 17.90 B | 12.85 B | 12.89 B |
| Gross Profit | 61.39 B | 83.22 B | 64.00 B | 57.07 B | 64.01 B | 65.20 B |
| SG&A Expense | 16.31 B | 13.22 B | 17.44 B | 17.88 B | 18.85 B | 16.11 B |
| R&D Expense | 17.79 B | 10.28 B | 14.65 B | 15.39 B | 11.69 B | 10.31 B |
| Operating Expenses | 34.33 B | 23.61 B | 32.26 B | 33.39 B | 30.56 B | 26.41 B |
| Operating Income | 27.06 B | 59.62 B | 31.74 B | 23.68 B | 33.45 B | 38.79 B |
| Pretax Income | 26.88 B | 62.17 B | 34.19 B | 25.52 B | 33.80 B | 37.03 B |
| Tax Provision | 5.89 B | 13.62 B | 7.29 B | 5.51 B | 7.30 B | 8.00 B |
| Net Income | 20.99 B | 48.56 B | 26.89 B | 20.01 B | 26.50 B | 29.03 B |
| EPS (Basic) | 4.74 | 10.93 | 6.06 | 4.50 | 5.96 | 6.54 |
| EPS (Diluted) | 4.74 | 10.91 | 6.04 | 4.50 | 5.96 | 6.53 |
| Shares Outstanding | 4.43 B | 4.44 B | 4.45 B | 4.45 B | 4.45 B | 4.44 B |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.